Technology Development: Page 2

FYR Dx, Medicover partner on assay, tech development
The firms plan to support pharmaceutical companies with clinical trial assay development and implementation, codevelopment of novel diagnostic technologies, and companion diagnostic testing services.
August 16, 2022
2020 03 25 23 27 0591 Hands Shaking Deal 400
Nucleai, Ultivue to partner on AI-based drug development platform
Under a comarketing agreement, the firms will integrate Nucleai's AI spatial models with Ultivue's imaging technology with the aim of speeding drug development.
June 5, 2022
2021 08 18 23 12 2135 Computer Ai Artificial Illustration 400
Hitachi High-Tech partners, invests in Invivoscribe
The partnership brings together Invivoscribe's technology, assay and bioinformatics development, global clinical testing, and international regulatory knowledge and Hitachi High-Tech's experience in measurement and analysis systems technologies.
May 9, 2022
2022 05 10 21 08 4981 Hands Shaking3 400
New task force promotes pathology for cancer research
Efforts of the task force include an award program for outstanding pathology research in cancer, knowledge hubs on pathology for medical students, and the development and adoption of new technologies in pathology. Parwani shed light on the new task force in an interview with LabPulse at the recent American Association for Cancer Research (AACR) meeting in New Orleans.
May 2, 2022
2022 05 03 13 14 8568 2022 05 02 Aacr Parwani 400
Huron Digital taps Audil Virk as president
Virk has executive leadership and operational experience in general management, strategy, product development, and technology commercialization, Huron said.
April 14, 2022
2020 03 25 23 27 0591 Hands Shaking Deal 400
MilliporeSigma closes Exelead buy for lipid nanoparticle boost
MilliporeSigma plans to invest more than $565 million over the next 10 years to further expand Exelead's PEGylated research and development and its LNP-based drug delivery technology, which is key to mRNA vaccines and therapeutics, MilliporeSigma said.
February 22, 2022
2021 05 26 16 06 9500 Global Collaboration Business 400
SLAS 2022: Diagnostics tech should be based on clinical need
Traditionally, scientists and engineers create a technology, find a biological application for it, and publish it in a big academic journal. For companies, the cycle is a bit different: a company creates a technology, most likely for life sciences research, and then years (if not decades) later, someone discovers a clinical application for it.
February 9, 2022
2020 06 04 19 23 9275 Lab Virus Bacteria Research 400
DiaCarta, NCI to work on cancer detection technology
Under a two-year Cooperative Research and Development Agreement (CRADA), the organizations will work on investigating low-frequency mutation events in cancers and rare diseases using DiaCarta's technology, as well as develop xenonucleic acid probes for in situ cancer cell detection.
January 6, 2022
2021 01 08 22 20 9120 Cancer Cell Target2 400
NIH announces accelerator diagnostics challenge
The contest aims to spur and reward the development of prototypes for low-cost, point-of-care molecular, cellular, and/or metabolic sensing and diagnostic technologies, the agency said in a release.
December 6, 2021
2020 07 07 21 16 8808 Pregnant Women Touching Belly 400
Point-of-care developer DCN Dx acquires IVD Vision
DCN Dx is a leading specialist developer of diagnostic tests based on lateral flow technology. The acquisition expands DCN Dx's POC diagnostics development services capabilities and product portfolio.
July 1, 2021
2020 07 02 23 31 0378 Handshake Meeting 400
Expanding NIPT coverage means nominal cost increase
HPHC, which covers around 3 million people in the northeastern U.S., partnered with Illumina and the University of Colorado for the study, which evaluated the effect of a risk-sharing agreement that opened insurance coverage for these women. For the agreement, Illumina and HPHC engaged the University of Colorado as a third-party academic collaborator in 2018 to develop a study protocol, complete the analyses, and lead the publication development. The PharmacoEconomics article is the first-ever published report on a value-based agreement between a bio/medical technology company and a payer, the groups said in a press release.
March 11, 2021
2019 04 01 22 25 7153 Pregnant Woman 400
Creator of Rutgers COVID-19 saliva test dies
The test earned Brooks recognition from numerous media outlets and New Jersey Gov. Phil Murphy.
January 28, 2021
2020 04 13 23 40 6039 Rutgersimage 400
Previous Page
Page 2 of 4
Next Page